Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

In classical Hodgkin lymphoma, circulating clonotypic malignant cells express CD20, which potentially explains the observed activity of rituximab. This multicenter phase 2 study investigated the combination of rituximab-ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage II-IV untreate...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Kasamon, Yvette L., Jacene, Heather A., Gocke, Christopher D., Swinnen, Lode J., Gladstone, Douglas E., Perkins, Brandy, Link, Brian K., Popplewell, Leslie L., Habermann, Thomas M., Herman, Joseph M., Matsui, William H., Jones, Richard J., Ambinder, Richard F.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2012
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3359734/
https://ncbi.nlm.nih.gov/pubmed/22343727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-01-402792
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia